DelveInsight’s, “Cannabinoid Pipeline Insight, 2025” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Cannabinoid pipeline landscape. It covers the Cannabinoid pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cannabinoid pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight’s comprehensive Cannabinoid Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ https://www.delveinsight.com/report-store/cannabinoid-pipeline-insight
Key Takeaways from the Cannabinoid Pipeline Report
- In January 2026, ZYUS Life Sciences Inc. initiated a study enrolling up to 20 patients to assess the preliminary analgesic efficacy and safety of Trichomylin® in male and female patients with advanced cancer experiencing moderate to severe chronic pain. Eligible participants were required to be on a stable regimen of long-acting opioid therapy for a minimum of one week prior to screening.
- DelveInsight’s Cannabinoid pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Cannabinoid treatment.
- The leading Cannabinoid Companies such as Harmony Biosciences, Cardiol Therapeutics, SciSparc, Argent BioPharma, Ananda Pharma, BRC Therapeutics, Avata Biosciences, InMed Pharmaceuticals Inc., MIRA Pharmaceuticals Inc., Bionorica SE, Neurotech International, Botanix SB Inc., Octavian Therapeutics, ZYUS Life Sciences Corp., Avicanna Inc., Raphael Pharmaceutical, EPM Therapeutics, Polyrizon, Artelo Biosciences, Virpax Pharmaceuticals and others.
- Promising Cannabinoid Pipeline Therapies such as ZYN-002, IHL-675A, IGC-AD1, SCI-110, BRC-002, SCI-160, Cannabidiol-loaded LPT, AP-707, ART27.13, OCT461201, AVAT 022 and others.
Discover how the Cannabinoid Treatment paradigm is evolving. Access DelveInsight’s in-depth Cannabinoid Pipeline Analysis for a closer look at promising breakthroughs @ Cannabinoid Pipeline Outlook
The Cannabinoid Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Cannabinoid Pipeline Report also highlights the unmet needs with respect to the Cannabinoid.
Cannabinoid Overview
A cannabinoid is a chemical compound that interacts with the body’s endocannabinoid system (ECS), a biological system involved in regulating functions such as pain, mood, appetite, memory, inflammation, and immune response. Cannabinoids exert their effects by binding to CB1 and CB2 receptors, primarily located in the brain, nervous system, and immune cells. Due to these interactions, cannabinoids are being explored for potential use in conditions such as chronic pain, epilepsy, multiple sclerosis, anxiety disorders, inflammatory diseases, and neurological conditions.
Cannabinoid Emerging Drugs Profile
- ZYN002: Harmony Biosciences
ZYN002 is the first-and-only pharmaceutically manufactured synthetic cannabidiol devoid of THC and formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. The product is manufactured through a synthetic process in a cGMP facility and is not extracted from the cannabis plant. ZYN002 does not contain THC, the compound that causes the euphoric effect of cannabis, and has the potential to be a nonscheduled product if approved. Currently, the drug is in Phase III stage of its clinical development for the treatment of Fragile X Syndrome.
- MRX1: Ananda Pharma
MRX1 is a high purity cannabidiol (CBD) formulation developed by Ananda Pharma as its lead investigational product. It is designed to target complex chronic inflammatory pain conditions such as chemotherapy induced peripheral neuropathy and endometriosis associated pain. The product is manufactured to pharmaceutical grade standards with a focus on consistency, safety, and regulatory compliance, positioning it as a potential therapeutic option in areas of high unmet medical need. Currently, the drug is in Phase II stage of its development for the treatment of Endometriosis-Associated Pain.
- BRC-002: BRC Therapeutics
BRC-002 is a first-in-class botanically derived oral therapy specifically designed to address the severe pain and associated co-morbidities of Complex Regional Pain Syndrome (CRPS), a rare and debilitating chronic pain condition with limited effective treatment options. According to company’s pipeline, the drug is in Phase I stage of its development for the treatment of Complex Regional Pain Syndrome (CRPS).
- INM-901: InMed Pharmaceuticals Inc.
INM‑901 is an investigational oral drug candidate developed by InMed Pharmaceuticals for the treatment of Alzheimer’s disease. It is a synthetic cannabinoid analog that targets CB1, CB2, and PPAR receptors, offering a multi-modal approach to neuroprotection and inflammation control. Preclinical studies show it enhances cognitive function, reduces neuroinflammation, and promotes neuronal growth. Its high lipophilicity allows it to cross the blood–brain barrier effectively. INM‑901 is currently in preclinical development with ongoing formulation and safety studies for Alzheimer’s disease.
The Cannabinoid Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Cannabinoid with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cannabinoid Treatment.
• Cannabinoid Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cannabinoid Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cannabinoid market
Explore groundbreaking therapies and clinical trials in the Cannabinoid Pipeline. Access DelveInsight’s detailed report now! @ Cannabinoid Ongoing Clinical Trials
Cannabinoid Companies
Harmony Biosciences, Cardiol Therapeutics, SciSparc, Argent BioPharma, Ananda Pharma, BRC Therapeutics, Avata Biosciences, InMed Pharmaceuticals Inc., MIRA Pharmaceuticals Inc., Bionorica SE, Neurotech International, Botanix SB Inc., Octavian Therapeutics, ZYUS Life Sciences Corp., Avicanna Inc., Raphael Pharmaceutical, EPM Therapeutics, Polyrizon, Artelo Biosciences, Virpax Pharmaceuticals and others.
Cannabinoid Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Cannabinoid Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Cannabinoid Market Drivers and Barriers
Scope of the Cannabinoid Pipeline Report
- Coverage- Global
- Cannabinoid Companies- Harmony Biosciences, Cardiol Therapeutics, SciSparc, Argent BioPharma, Ananda Pharma, BRC Therapeutics, Avata Biosciences, InMed Pharmaceuticals Inc., MIRA Pharmaceuticals Inc., Bionorica SE, Neurotech International, Botanix SB Inc., Octavian Therapeutics, ZYUS Life Sciences Corp., Avicanna Inc., Raphael Pharmaceutical, EPM Therapeutics, Polyrizon, Artelo Biosciences, Virpax Pharmaceuticals and others.
- Cannabinoid Pipeline Therapies- ZYN-002, IHL-675A, IGC-AD1, SCI-110, BRC-002, SCI-160, Cannabidiol-loaded LPT, AP-707, ART27.13, OCT461201, AVAT 022 and others.
- Cannabinoid Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Cannabinoid Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Cannabinoid drug development? Find out in DelveInsight’s exclusive Cannabinoid Pipeline Report-access it now! @ Cannabinoid Major Companies
Table of Contents
- Introduction
- Executive Summary
- Cannabinoids: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Cannabinoids– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- ZYN-002: Harmony Biosciences
- Mid Stage Products (Phase II)
- SCI-110: SciSparc
- Early Stage Products (Phase I)
- BRC-002: BRC Therapeutics
- Preclinical and Discovery Stage Products
- INM-901: InMed Pharmaceuticals Inc.
- Inactive Products
- Cannabinoids Key Companies
- Cannabinoids Key Products
- Cannabinoids- Unmet Needs
- Cannabinoids- Market Drivers and Barriers
- Cannabinoids- Future Perspectives and Conclusion
- Cannabinoids Analyst Views
- Cannabinoids Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consultinCannabinoid Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Domain | DelveInsightg firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
